Pharmaceutical Laboratory Articles & Analysis: Older
23 news found
Boston: “According to the latest BCC Research study, the demand for Medical Kiosks: Global Market and Forecasts is estimated to increase from $1.4 billion in 2022 to reach $3.2 billion by 2028, at a compound annual growth rate (CAGR) of 14.8% from 2022 through 2028.” The comprehensive report on the medical kiosks market delivers a thorough analysis of its current landscape and future ...
Stefan Blomsterberg has been appointed as the new CEO of CELLINK. Cecilia Edebo, current CEO, requested earlier this year to resign from her position to pursue a new career opportunity outside the BICO Group. At the time of her resignation, a recruitment process was initiated which concluded in the appointment of Stefan Blomsterberg. Stefan Blomsterberg (born 1964) brings 20+ years of experience ...
ByCELLINK
CELLINK and Ossiform have entered a strategic partnership to join forces to commercialize a ready-to-print bioink based on Ossiform’s existing biomaterial. Sales of the material will begin in 2024 and will be distributed co-exclusively through CELLINK’s commercial channels. Bone regeneration is one of the fastest growing research disciplines, given the massive impact it can have on ...
ByCELLINK
CELLINK, a global leader in bioprinting technologies, is proud to announce a pioneering innovation in the field of regenerative medicine and tissue engineering with the launch of CELLINK Vivoink, the first-ever medical-grade bioink specially designed to support researchers on their clinical translational journey. CELLINK Vivoink is optimized for superior printability, mechanical stability, and ...
ByCELLINK
Today, the company’s best-in-class bioinks, bioprinters, software and services have been cited in over 1000 publications and are trusted by more than 1,600 academic, pharmaceutical and industrial labs. With a comprehensive portfolio of world-class 3D bioprinters and bioinks CELLINK’s technology enables the printing of human tissues and organs, which enable faster and ...
ByCELLINK
TOMI Environmental Solutions, Inc.® ("TOMI") (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, today announced that the Company has entered into a contract with Vizient, Inc. increasing TO Mi's presence in the U.S. healthcare system. Vizient is the largest group purchasing organization (GPO) in the healthcare industry supplying around $100 billion in ...
FREDERICK, Md., March 13, 2023 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, today announced it will report results for the fourth quarter ended December 31, 2022, after the close of the financial markets on Thursday, March 16, 2023 and will hold a conference call at ...
FREDERICK, Md., Jan. 25, 2023 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, announces that TOMI will present its SteraMist brand of products at three upcoming International Society for Pharmaceutical Engineering (ISPE) Conferences in the first quarter of 2023: The ISPE ...
FREDERICK, Md., Jan. 17, 2023 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, announces that the National Health Services (NHS) Wales purchased SteraMist ionized Hydrogen Peroxide (iHP) technology further expanding presence in Great Britain. NHS Wales is a publicly funded ...
Today, DNAnexus has more than 12,000 users across 48 countries and works with the largest and most innovative pharmaceutical companies, diagnostic laboratories, and academic medical centers around the world, along with the UK Biobank and the FDA. ...
n response to President Biden’s relaunch of Cancer Moonshot and his White House commitment to end cancer as we know it, healthcare technology executives for CureMetrix and CureMatch highlighted joint innovation as core to better detection and more personalized cancer treatment. “We commend President Biden’s program to end cancer as we know it, which starts with early detection ...
Sheriff was the VP, Regulatory Affairs and Quality Assurance at Celerity Pharmaceuticals, where she obtained ten regulatory approvals in over six years in the role. ...
Frontier Biotech (stock code: 688221.SH) announces that it signs an agreement with R-Pharm, JSC, one of the largest pharmaceutical companies in Russia, for registration and commercialization of Aikening® (generic name: Albuvirtide) in Russia. ...
ECAT has proven to be a successful acquisition strategy that allows customers to browse, compare, and order a wide range of pharmaceutical, laboratory, dental, optical fabrication, and medical/surgical equipment commercial items. ...
Our company, as one of the largest manufacturers of pharmaceutical refrigerators and ultra-low freezers, is also actively involved in this program. ...
The acquisition will enable UK based UK Gas Technologies, which was founded in 1983, to maintain momentum as an international innovator in custom-made solutions for high purity medical and laboratory gases, purified water and steam systems, and other process installations and specialist systems, serving clients worldwide in sectors including healthcare and hospitals, ...
As pharmaceutical labs turn to cryo-electron microscopy (cryo-EM) to uncover the structures of difficult-to-crystalize molecules at near atomic resolution, they need ways to increase their productivity to more quickly move from early drug discovery to clinical trials. ...
Utilization of the 152a molecule as a lower GWP inhaler propellant addresses concerns of both patients and pharmaceutical companies. 1 Clinical trials with Zephex® 152a will take place in the United States and are expected to begin in February 2020 and conclude within Q1. ...
ByKoura
"The new Center reinforces our mission of enabling our customers to make the world healthier, cleaner and safer by helping laboratories in China nurture innovation and bring effective medicines to waiting patients." Zhong Feng, director, Shandong New Time Pharmaceutical Co., LTD., said, "Thermo Fisher's new Customer Solution Center in Shanghai is a hub of ...
The orphan designation for ZENEO® Midazolam improves Crossject’s international visibility and gives impetus to its current negotiations for partnerships with pharmaceutical laboratories. ...